Abstract
Purpose: Sentinel lymph node biopsy (SLNB) is the gold-standard procedure for evaluating axillary lymph node (ALN) status in patients with breast cancer. However, the morbidity of SLNB is not negligible, and the procedure is invasive for patients without ALN metastasis. Here, we developed a diagnostic model for evaluating ALN status using a combination of serum miRNAs and clinicopathologic factors as a novel less-invasive biomarker. Experimental Design: Preoperative serum samples were collected from patients who underwent surgery for primary breast cancer or breast benign diseases between 2008 and 2014. A total of 958 serum samples (921 cases of primary breast cancer, including 630 cases in the no ALN metastasis group and 291 cases in the ALN metastasis group, and 37 patients with benign breast diseases) were analyzed by miRNA microarray. Samples were randomly divided into training and test sets. Logistic LASSO regression analysis was used to construct diagnostic models in the training set, which were validated in the test set. Results: An optimal diagnostic model was identified using a combination of two miRNAs (miR-629-3p and miR-4710) and three clinicopathologic factors (T stage, lymphovascular invasion, and ultrasound findings), which showed a sensitivity of 0.88 (0.84–0.92), a specificity of 0.69 (0.61–0.76), an accuracy of 0.818, and an area under the receiver operating characteristic curve of 0.86 in the test set. Conclusions: Serum miRNA profiles may be useful for the diagnosis of ALN metastasis before surgery in a less-invasive manner than SLNB.
| Original language | English |
|---|---|
| Pages (from-to) | 1817-1827 |
| Number of pages | 11 |
| Journal | Clinical Cancer Research |
| Volume | 25 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 2019 Jan 1 |
Fingerprint
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Serum miRNA–based Prediction of Axillary Lymph Node Metastasis in Breast Cancer. / Shiino, Sho; Matsuzaki, Juntaro; Shimomura, Akihiko; Kawauchi, Junpei; Takizawa, Satoko; Sakamoto, Hiromi; Aoki, Yoshiaki; Yoshida, Masayuki; Tamura, Kenji; Kato, Ken; Kinoshita, Takayuki; Kitagawa, Yuukou; Ochiya, Takahiro.
In: Clinical Cancer Research, Vol. 25, No. 6, 01.01.2019, p. 1817-1827.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Serum miRNA–based Prediction of Axillary Lymph Node Metastasis in Breast Cancer
AU - Shiino, Sho
AU - Matsuzaki, Juntaro
AU - Shimomura, Akihiko
AU - Kawauchi, Junpei
AU - Takizawa, Satoko
AU - Sakamoto, Hiromi
AU - Aoki, Yoshiaki
AU - Yoshida, Masayuki
AU - Tamura, Kenji
AU - Kato, Ken
AU - Kinoshita, Takayuki
AU - Kitagawa, Yuukou
AU - Ochiya, Takahiro
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Purpose: Sentinel lymph node biopsy (SLNB) is the gold-standard procedure for evaluating axillary lymph node (ALN) status in patients with breast cancer. However, the morbidity of SLNB is not negligible, and the procedure is invasive for patients without ALN metastasis. Here, we developed a diagnostic model for evaluating ALN status using a combination of serum miRNAs and clinicopathologic factors as a novel less-invasive biomarker. Experimental Design: Preoperative serum samples were collected from patients who underwent surgery for primary breast cancer or breast benign diseases between 2008 and 2014. A total of 958 serum samples (921 cases of primary breast cancer, including 630 cases in the no ALN metastasis group and 291 cases in the ALN metastasis group, and 37 patients with benign breast diseases) were analyzed by miRNA microarray. Samples were randomly divided into training and test sets. Logistic LASSO regression analysis was used to construct diagnostic models in the training set, which were validated in the test set. Results: An optimal diagnostic model was identified using a combination of two miRNAs (miR-629-3p and miR-4710) and three clinicopathologic factors (T stage, lymphovascular invasion, and ultrasound findings), which showed a sensitivity of 0.88 (0.84–0.92), a specificity of 0.69 (0.61–0.76), an accuracy of 0.818, and an area under the receiver operating characteristic curve of 0.86 in the test set. Conclusions: Serum miRNA profiles may be useful for the diagnosis of ALN metastasis before surgery in a less-invasive manner than SLNB.
AB - Purpose: Sentinel lymph node biopsy (SLNB) is the gold-standard procedure for evaluating axillary lymph node (ALN) status in patients with breast cancer. However, the morbidity of SLNB is not negligible, and the procedure is invasive for patients without ALN metastasis. Here, we developed a diagnostic model for evaluating ALN status using a combination of serum miRNAs and clinicopathologic factors as a novel less-invasive biomarker. Experimental Design: Preoperative serum samples were collected from patients who underwent surgery for primary breast cancer or breast benign diseases between 2008 and 2014. A total of 958 serum samples (921 cases of primary breast cancer, including 630 cases in the no ALN metastasis group and 291 cases in the ALN metastasis group, and 37 patients with benign breast diseases) were analyzed by miRNA microarray. Samples were randomly divided into training and test sets. Logistic LASSO regression analysis was used to construct diagnostic models in the training set, which were validated in the test set. Results: An optimal diagnostic model was identified using a combination of two miRNAs (miR-629-3p and miR-4710) and three clinicopathologic factors (T stage, lymphovascular invasion, and ultrasound findings), which showed a sensitivity of 0.88 (0.84–0.92), a specificity of 0.69 (0.61–0.76), an accuracy of 0.818, and an area under the receiver operating characteristic curve of 0.86 in the test set. Conclusions: Serum miRNA profiles may be useful for the diagnosis of ALN metastasis before surgery in a less-invasive manner than SLNB.
UR - http://www.scopus.com/inward/record.url?scp=85062971315&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062971315&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-18-1414
DO - 10.1158/1078-0432.CCR-18-1414
M3 - Article
C2 - 30482779
AN - SCOPUS:85062971315
VL - 25
SP - 1817
EP - 1827
JO - Clinical Cancer Research
JF - Clinical Cancer Research
SN - 1078-0432
IS - 6
ER -